ADC Therapeutics - Resources

On what stock exchange are ADC Therapeutics’ shares traded, and what is the ticker symbol? When was ADC Therapeutics’ Initial Public Offering? Where is ADC Therapeutics’ corporate headquarters? Who are the members of ADC Therapeutics’ Board of Directors and Leadership Team? Who is ADC Therapeutics’ legal counsel? How do I buy stock in ADCT? How do I contact Investor Relations with a question or request? How can I obtain a copy of the Company’s Annual Report?

On what stock exchange are ADC Therapeutics’ shares traded, and what is the ticker symbol?

The ADC Therapeutics ticker is ADCT and is traded on the New York Stock Exchange.

When was ADC Therapeutics’ Initial Public Offering?

May 15, 2020

Where is ADC Therapeutics’ corporate headquarters?

Biopôle
Route de la Corniche 3B
1066 Epilanges, Switzerland

Who are the members of ADC Therapeutics’ Board of Directors and Leadership Team?

View the Board of Directors here and Leadership Team here.

Who is ADC Therapeutics’ legal counsel?

Davis Polk & Wardwell LLP: 450 Lexington Avenue, New York, NY 10017
Homburger AG: Hardstrasse 201, 8005 Zurich, Switzerland

How do I buy stock in ADCT?

ADC Therapeutics does not currently have a direct stock purchase plan. In order to buy stock, you must contact your broker.

How do I contact Investor Relations with a question or request?

You can contact Amanda Hamilton in the Investor Relations department at Amanda.Hamilton@adctherapeutics.com.

How can I obtain a copy of the Company’s Annual Report?

The Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission and its Swiss statutory annual report for the fiscal year ended December 31, 2020 are available at ir.adctherapeutics.com under “Events and Presentations”. Shareholders may receive a hard copy of the Company’s audited financial statements, or its complete Annual Report including audited financial statements, free of charge, by requesting a copy from Investor Relations at Amanda.Hamilton@adctherapeutics.com. Any requests for hard copies may be subject to a delay in mailing due to the COVID-19 pandemic.

Investor FAQs